Literature DB >> 26819656

Academic-Industrial Collaboration: Toward the Consilience of Two Solitudes.

Stephen Hanessian1.   

Abstract

Current major advances in drug discovery can be traced back to pioneering contributions originating from academics over a century ago. Living in a symbiotic yet noninvasive coexistence, the academic community and the pharmaceutical industry have strived, each in their own way, to develop the modern medicines that benefit humankind today. The subject is presented from a historical and personal perspective.

Keywords:  Natural products; drug discovery; medicinal chemistry; targeted research

Year:  2015        PMID： 26819656      PMCID： PMC4716587          DOI： 10.1021/acsmedchemlett.5b00488

Source DB:  PubMed          Journal:  ACS Med Chem Lett        ISSN： 1948-5875            Impact factor:   4.345


  25 in total

1.  Lack of proteasome active site allostery as revealed by subunit-specific inhibitors.

Authors:  J Myung; K B Kim; K Lindsten; N P Dantuma; C M Crews
Journal:  Mol Cell       Date:  2001-02       Impact factor: 17.970

Review 2.  Outlook: finding improved medicines: the role of academic-industrial collaboration.

Authors:  Jaye Chin-Dusting; Jacques Mizrahi; Garry Jennings; Desmond Fitzgerald
Journal:  Nat Rev Drug Discov       Date:  2005-11       Impact factor: 84.694

3.  Why academic drug discovery makes sense.

Authors:  Alan P Kozikowski; Bryan Roth; Alexander Tropsha
Journal:  Science       Date:  2006-09-01       Impact factor: 47.728

4.  The advent and development of organocatalysis.

Authors:  David W C MacMillan
Journal:  Nature       Date:  2008-09-18       Impact factor: 49.962

Review 5.  Lessons from 60 years of pharmaceutical innovation.

Authors:  Bernard Munos
Journal:  Nat Rev Drug Discov       Date:  2009-12       Impact factor: 84.694

6.  The role of public-sector research in the discovery of drugs and vaccines.

Authors:  Ashley J Stevens; Jonathan J Jensen; Katrine Wyller; Patrick C Kilgore; Sabarni Chatterjee; Mark L Rohrbaugh
Journal:  N Engl J Med       Date:  2011-02-10       Impact factor: 91.245

Review 7.  The cost of drug development: a systematic review.

Authors:  Steve Morgan; Paul Grootendorst; Joel Lexchin; Colleen Cunningham; Devon Greyson
Journal:  Health Policy       Date:  2011-01-21       Impact factor: 2.980

Review 8.  Dimethyl sulfoxide to vorinostat: development of this histone deacetylase inhibitor as an anticancer drug.

Authors:  Paul A Marks; Ronald Breslow
Journal:  Nat Biotechnol       Date:  2007-01       Impact factor: 54.908

9.  Potent and selective inhibitors of the proteasome: dipeptidyl boronic acids.

Authors:  J Adams; M Behnke; S Chen; A A Cruickshank; L R Dick; L Grenier; J M Klunder; Y T Ma; L Plamondon; R L Stein
Journal:  Bioorg Med Chem Lett       Date:  1998-02-17       Impact factor: 2.823

Review 10.  An overview of FDA-approved new molecular entities: 1827-2013.

Authors:  Michael S Kinch; Austin Haynesworth; Sarah L Kinch; Denton Hoyer
Journal:  Drug Discov Today       Date:  2014-03-26       Impact factor: 8.369
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.